Drug Profile
Research programme: therapeutic drug formulations - ImprimisRx
Alternative Names: Bacitracin/tranexamic-acid; IPI-120; Tranexamic acid/bacitracin; Wound management therapeutics - ImprimisRxLatest Information Update: 14 Jan 2019
Price :
$50
*
At a glance
- Originator Buderer Drug Co
- Developer ImprimisRx
- Class Cyclic peptides; Cyclohexanecarboxylic acids; Small molecules
- Mechanism of Action Plasminogen activator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dental caries; Unspecified; Wound infections; Wounds
Most Recent Events
- 31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
- 28 Jul 2018 No recent reports of development identified for preclinical development in Wound-infections in USA (Transdermal)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Wounds in USA (Transdermal)